Panion & Bf BiotechTPE:1760 74 Market Cap is NT$5,222 Mil as of Jul. 02, 2026. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$96.00 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,427 Biotechnology companies, Panion & Bf Biotech ranks better than 54.59% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Panion & Bf Biotech's share price for the quarter that ended in Dec. 2025 was NT$63. Panion & Bf Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 86 Mil. Therefore, Panion & Bf Biotech's market cap for the quarter that ended in Dec. 2025 was NT$5,402 Mil.
Panion & Bf Biotech's quarterly market cap
declined
from Jun. 2025 (NT$6,199 Mil) to Sep. 2025 (NT$6,070 Mil) and
declined
from Sep. 2025 (NT$6,070 Mil) to Dec. 2025 (NT$5,402 Mil).
Panion & Bf Biotech's annual market cap
declined
from Dec. 2023 (NT$9,603 Mil) to Dec. 2024 (NT$7,039 Mil) and
declined
from Dec. 2024 (NT$7,039 Mil) to Dec. 2025 (NT$5,402 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Panion & Bf Biotech's Enterprise Value for Today is NT$5,409 Mil.
Panion & Bf Biotech (TPE:1760) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Panion & Bf Biotech Market Cap Related Terms
Panion & Bf Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Panion & Bf Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panion & Bf Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Panion & Bf Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a Market Cap of NT$5,222 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Panion & Bf Biotech and its competitors. According to the industry distribution chart, Panion & Bf Biotech ranks #648 out of 1427 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Panion & Bf Biotech's Market Cap too high?
Panion & Bf Biotech's current Market Cap is NT$5,222 Mil. Based on the distribution chart, Panion & Bf Biotech ranks #648 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panion & Bf Biotech ranks #648 out of 1427 companies for Market Cap. This puts Panion & Bf Biotech in the upper half of its industry. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Panion & Bf Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current Market Cap is NT$5,222 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.00, compared to a current price of NT$60.90 — trading 36.6% below its estimated fair value. The current Market Cap is NT$5,222 Mil. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Market Cap is NT$5,222 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$60.90 is trading 36.6% below its estimated GF Value™ of NT$96.00.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
Market Cap: NT$5,222 Mil
GF Value™: NT$96.00 vs. price of NT$60.90 (36.6% below fair value)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score
Get the complete analysis for TPE:1760
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
